

Table 1. Mutation status and IC<sub>50</sub>( $\mu$ M) for Dovitinib and Oxaliplatin in Colon Cancer Cell Lines

| <b>Cell Lines</b><br><i>Status</i><br><i>Drugs</i> | <b>HCT-116</b>     | <b>HT-29</b>          | <b>SW-480</b>                        | <b>CaCO2</b>        | <b>LS174T</b>      |
|--|--------------------|-----------------------|--------------------------------------|---------------------|--------------------|
| <b>KRAS</b>  | <b>M(Gly13Asp)</b> | <b>WT</b>             | <b>M(Gly12Val)</b>                   | <b>WT</b>           | <b>M(Gly12Asp)</b> |
| <b>BRAF</b>  | <b>WT</b>          | <b>M(Val600Glu)</b>   | <b>WT</b>                            | <b>M(Val600Glu)</b> | <b>WT</b>          |
| <b>PIK3CA/pTEN</b>                                 | <b>M</b>           | <b>WT</b>             | <b>WT</b>                            | <b>WT</b>           | <b>M</b>           |
| <b>p53</b>   | <b>WT</b>          | <b>M (273Arg-His)</b> | <b>M (273Arg-His<br/>309Pro-ser)</b> | <b>M</b>            | <b>WT</b>          |
| <b>LOH/MSI</b>                                     | <b>MSI</b>         | <b>MSS/LOH</b>        | <b>MSS/LOH</b>                       | <b>MSS</b>          | <b>MSI</b>         |
| <b>APC</b>   | <b>WT</b>          | <b>M</b>              | <b>M</b>                             | <b>M</b>            | <b>WT</b>          |
| <b>Dovitinib</b>                                   | <b>3.05 0.58</b>   | <b>5.2 1.93</b>       | <b>4.33 0.47</b>                     | <b>3.23 0.64</b>    | <b>4.33 0.47</b>   |
| <b>Oxaliplatin</b>                                 | <b>1.67 0.17</b>   | <b>8.0 2.0</b>        | <b>6.0 2.08</b>                      | <b>2.7 0.15</b>     | <b>2.87 1.27</b>   |

Abbreviations: M-Mutant, WT- Wild type, LOH-loss of heterozygosity, MSI- Microsatellite instability, MSS- Microsatellite stable